Millennium, of Cambridge Mass., has rescued the kinase inhibitor program in oncology at Sunesis Pharmaceuticals Inc. after development partner Biogen Idec exited the oncology market last fall. Millennium, a unit of Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, inked a licensing agreement that covers the development of Sunesis' oral, Phase I-ready selective pan-Raf kinase inhibitor and an additional preclinical kinase inhibitor program with an undisclosed oncology target.